Erasca Inc
ERAS2.270USD
+0.030+1.34%
收盘 11/07, 16:00（美东）报价延迟15分钟
643.89M总市值
亏损市盈率 TTM
关于 Erasca Inc 公司
Erasca, Inc. 是一家临床阶段精准肿瘤学公司。该公司专注于发现、开发和商业化针对 RAS/MAPK 通路驱动癌症患者的疗法。该公司已在行业内组建了全资或控制的以 RAS/MAPK 通路为重点的管线，该管线专注于与其三种治疗策略相一致的模式无关项目：针对 RAS/MAPK 通路中的关键上游和下游信号传导节点；直接针对 RAS；以及针对治疗后出现的逃逸途径。其管线包括三个临床阶段项目，例如泛 RAF 抑制剂、ERK 抑制剂和中枢神经系统 (CNS) 渗透性 EGFR 抑制剂，以及针对其他关键致癌驱动因素的其他发现阶段项目。其主要候选产品是纳帕非尼，一种泛 RAF 抑制剂，可用于治疗 NRAS 突变 (NRASm) 黑色素瘤、RAS Q61X 实体瘤和其他 RAS/MAPK 通路驱动肿瘤患者。
Erasca Inc简介
公司代码ERAS
公司名称Erasca Inc
上市日期Jul 15, 2021
CEODr. Jonathan E. Lim, M.D.
员工数量103
证券类型Ordinary Share
年结日Jul 15
公司地址3115 Merryfield Row
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92121
电话18584656511
网址https://www.erasca.com/
公司代码ERAS
上市日期Jul 15, 2021
CEODr. Jonathan E. Lim, M.D.
Erasca Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
21.17K
+37.11%
Dr. Shannon R. Morris, M.D., Ph.D.
Dr. Shannon R. Morris, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
--
--
Dr. Valerie Harding-Start, Ph.D.
Dr. Valerie Harding-Start, Ph.D.
Independent Director
Independent Director
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Independent Director
Independent Director
--
--
Dr. Michael David Varney, Ph.D.
Dr. Michael David Varney, Ph.D.
Director, Chair of Research and Development and Scientific Advisory Board member
Director, Chair of Research and Development and Scientific Advisory Board member
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
21.17K
+37.11%
Dr. Shannon R. Morris, M.D., Ph.D.
Dr. Shannon R. Morris, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
8.01%
T. Rowe Price Investment Management, Inc.
7.17%
Lim (Jonathan E)
6.86%
VR Adviser, LLC
6.29%
Logos Global Management LP
5.29%
其他
66.38%
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
8.01%
T. Rowe Price Investment Management, Inc.
7.17%
Lim (Jonathan E)
6.86%
VR Adviser, LLC
6.29%
Logos Global Management LP
5.29%
其他
66.38%
股东类型
持股股东
占比
Investment Advisor
27.40%
Venture Capital
21.13%
Hedge Fund
17.22%
Private Equity
8.01%
Individual Investor
7.34%
Investment Advisor/Hedge Fund
6.87%
Corporation
4.34%
Research Firm
1.12%
Bank and Trust
0.10%
其他
6.46%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
308
232.32M
81.90%
-33.10M
2025Q2
309
274.17M
96.78%
-35.25M
2025Q1
317
274.49M
97.07%
-35.76M
2024Q4
322
280.04M
99.05%
-35.03M
2024Q3
313
281.15M
102.27%
+61.97K
2024Q2
303
252.04M
113.79%
+64.87M
2024Q1
280
120.99M
80.07%
-2.11M
2023Q4
270
117.59M
77.97%
+472.06K
2023Q3
257
122.33M
82.97%
-7.99M
2023Q2
252
125.95M
86.10%
-5.27M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Frazier Life Sciences Management, L.P.
22.73M
8.01%
+153.59K
+0.68%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
20.33M
7.17%
+3.04M
+17.58%
Jun 30, 2025
Lim (Jonathan E)
19.46M
6.86%
--
--
Apr 15, 2025
VR Adviser, LLC
17.86M
6.29%
+1.64M
+10.12%
Jun 30, 2025
Logos Global Management LP
15.00M
5.29%
+2.00M
+15.38%
Jun 30, 2025
Suvretta Capital Management, LLC
14.50M
5.11%
+2.19M
+17.76%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
13.32M
4.7%
-725.47K
-5.16%
Jun 30, 2025
City Hill Ventures, LLC
12.90M
4.55%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
12.70M
4.48%
+9.22K
+0.07%
Jun 30, 2025
Novartis Pharma AG
12.31M
4.34%
--
--
Dec 31, 2024
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
1.03%
ALPS Medical Breakthroughs ETF
0.36%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.03%
ProShares UltraPro Russell2000
0.01%
Schwab U.S. Small-Cap ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比1.03%
ALPS Medical Breakthroughs ETF
占比0.36%
Invesco Nasdaq Biotechnology ETF
占比0.07%
iShares Micro-Cap ETF
占比0.07%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
iShares Biotechnology ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.03%
Fidelity Enhanced Small Cap ETF
占比0.03%
ProShares UltraPro Russell2000
占比0.01%
Schwab U.S. Small-Cap ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
